The most established of these is TRC105, an endoglin antibody that has been studied for the treatment of multiple solid tumor types, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, hepatocellular carcinoma and colorectal cancer (Rosen et al. This evidence concerns the gene ENG and colorectal cancer.